24 September 2020 - Late treatment study
Ivermectin treatment may improve the prognosis of patients with COVID-19
et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.08.007 (Letter)
Retrospective 115 ivermectin patients and 133 control patients showing significantly lower death and faster viral clearance. Some potential issues and the authors' response can be found in [1, 2].
|
risk of death, 87.1% lower, RR 0.13, p = 0.02, treatment 1 of 115 (0.9%), control 9 of 133 (6.8%), NNT 17.
|
|
risk of ICU admission, 89.5% lower, RR 0.11, p = 0.007, treatment 1 of 115 (0.9%), control 11 of 133 (8.3%), NNT 14.
|
|
risk of progression, 83.5% lower, RR 0.17, p < 0.001, treatment 3 of 115 (2.6%), control 21 of 133 (15.8%), NNT 7.6.
|
|
risk of no recovery, 87.1% lower, RR 0.13, p = 0.02, treatment 1 of 115 (0.9%), control 9 of 133 (6.8%), NNT 17.
|
|
hospitalization time, 40.0% lower, relative time 0.60, p < 0.001, treatment 115, control 133.
|
|
time to viral-, 73.3% lower, relative time 0.27, p < 0.001, treatment 115, control 133.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Khan et al., 9/24/2020, retrospective, Bangladesh, South Asia, preprint, median age 35.0, 8 authors, dosage 12mg single dose.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC.